» Articles » PMID: 34020126

Residual Ground Glass Opacities Three Months After Covid-19 Pneumonia Correlate to Alteration of Respiratory Function: The Post Covid M3 Study

Abstract

Introduction: Lung function in survivors of SARS-Co-V2 pneumonia is poorly known, but concern over the possibility of sequelae exists.

Methods: Retrospective study on survivors with confirmed infection and pneumonia on chest-CT. Correlations between PFT and residual radiologic anomalies at three months taking into account initial clinical and radiological severity and steroid use during acute phase.

Results: 137 patients (69 men, median age 59 (Q1 50; Q3 68), BMI 27.5 kg/m (25.1; 31.7)) were assessed. Only 32.9% had normal PFT, 75 had altered DLCO. Median (Q1; Q3) values were: VC 79 (66; 92) % pred, FEV1 81 (68; 89), TLC 78 (67; 85), DLCO 60 (44; 72), and KCO 89 (77; 105). Ground glass opacities (GGO) were present in 103 patients (75%), reticulations in 42 (30%), and fibrosis in 18 (13%). There were significantly lower FEV1 (p = 0.0089), FVC (p = 0.0010), TLC (p < 0.0001) and DLCO (p < 0.0001) for patients with GGO, lower TLC (p = 0.0913) and DLCO (p = 0.0181) between patients with reticulations and lower FVC (p = 0.0618), TLC (p = 0.0742) DLCO (p = 0.002) and KCO (p = 0.0114) between patients with fibrosis. Patients with initial ≥50% lung involvement had significantly lower FEV1 (p = 0.0019), FVC (p = 0.0033), TLC (p = 0.0028) and DLCO (p = 0.0003) compared to patients with ≤10%. There was no difference in PFT and residual CT lesions between patients who received steroids and those who did not.

Conclusion: The majority of patients have altered PFT at three months, even in patients with mild initial disease, with significantly lower function in patients with residual CT lesions. Steroids do not seem to modify functional and radiological recovery. Long-term follow-up is needed.

Citing Articles

Erector Spinae Muscle to Epicardial Visceral Fat Ratio on Chest CT Predicts the Severity of Coronavirus Disease 2019.

Shimada T, Maetani T, Chubachi S, Tanabe N, Asakura T, Namkoong H J Cachexia Sarcopenia Muscle. 2025; 16(1):e13721.

PMID: 39868664 PMC: 11770476. DOI: 10.1002/jcsm.13721.


Cardiovascular abnormalities of long-COVID syndrome: Pathogenic basis and potential strategy for treatment and rehabilitation.

Wu K, Van Name J, Xi L Sports Med Health Sci. 2024; 6(3):221-231.

PMID: 39234483 PMC: 11369840. DOI: 10.1016/j.smhs.2024.03.009.


Pulmonary function 3-6 months after acute COVID-19: A systematic review and multicentre cohort study.

Cornelissen M, Leliveld A, Baalbaki N, Gach D, van der Lee I, Nossent E Heliyon. 2024; 10(6):e27964.

PMID: 38533004 PMC: 10963328. DOI: 10.1016/j.heliyon.2024.e27964.


Nivolumab Safety in Renal Cell Carcinoma: A Case Report.

Debono J, Balzan D, Borg J, Falzon S, Al-Haddad D, Micallef B J Pharm Technol. 2024; 40(2):112-117.

PMID: 38525093 PMC: 10959086. DOI: 10.1177/87551225231218164.


Mitogen-activated protein kinase-guided drug discovery for post-viral and related types of lung disease.

Holtzman M, Zhang Y, Wu K, Romero A Eur Respir Rev. 2024; 33(171).

PMID: 38417971 PMC: 10900067. DOI: 10.1183/16000617.0220-2023.


References
1.
Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J . Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection. 2020; 48(4):543-551. PMC: 7186187. DOI: 10.1007/s15010-020-01432-5. View

2.
Li T, Gomersall C, Joynt G, Chan D, Leung P, Hui D . Long-term outcome of acute respiratory distress syndrome caused by severe acute respiratory syndrome (SARS): an observational study. Crit Care Resusc. 2007; 8(4):302-8. View

3.
Hui D, Joynt G, Wong K, Gomersall C, Li T, Antonio G . Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005; 60(5):401-9. PMC: 1758905. DOI: 10.1136/thx.2004.030205. View

4.
Zhao Y, Shang Y, Song W, Li Q, Xie H, Xu Q . Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020; 25:100463. PMC: 7361108. DOI: 10.1016/j.eclinm.2020.100463. View

5.
Revel M, Parkar A, Prosch H, Silva M, Sverzellati N, Gleeson F . COVID-19 patients and the radiology department - advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). Eur Radiol. 2020; 30(9):4903-4909. PMC: 7170031. DOI: 10.1007/s00330-020-06865-y. View